Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Reexamination Certificate
2000-04-14
2001-06-12
Criares, Theodore J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
Reexamination Certificate
active
06245820
ABSTRACT:
DESCRIPTION
1. Technical Field
The present invention relates to a medicine for the treatment of Meniere's disease containing erythritol as an active ingredient.
2. Background Art
Meniere's disease is a disease of unknown cause, but it has been reported to be an endolymphatic hydrops by nature. It is believed that endolymphatic fluid accumulates due to excess production of endolymphatic fluid or due to disorders in absorption, whereby the endolymphatic hydrops is formed and the Reissner's membranes of the cochlear duct is risen and, as a result, symptoms such as ringing of the ears, hearing difficulties, dizziness, and a feeling of blocked ears are generated.
In the past, as a medicine for the treatment of Meniere's disease, the osmotic pressure diuretic medicine, Isosorbide (i.e., 1,4:3,6-dianhydro-D-sorbitol) has been used as an oral administration agent for the purpose of alleviating the endolymphatic hydrops. However, the osmotic pressure diuretic medicine, Isosorbide currently, which is clinically applied as a medicine for the treatment of Meniere's disease has difficulties in the viewpoint of taste. Further, it is a liquid, and therefore, there is the problem of inconvenience in the transportation.
DISCLOSURE OF THE INVENTION
Accordingly, an object of the present invention is to provide a medicine for the treatment of Meniere's disease which is superior in the viewpoint of taste, is capable of reducing the amount of the medicine to be administered by improving the type of formulation, and is easy to take by patients.
In accordance with the present invention, there is provided a medicine for the treatment of Meniere's disease comprising erythritol as an active ingredient.
REFERENCES:
patent: 5916606 (1999-06-01), Record et al.
patent: 63-230627 (1988-09-01), None
patent: 7-103017 (1994-07-01), None
patent: 10-36255 (1998-02-01), None
D. Yazawa, “Histopathological Study of Endolymphatic Hydrops”, Jibi Rinsho 74, pp. 2450 to 2506 (1981).
M. M. Paparella et al, “Endolymphatic Hydrops and Otitis media”, The Laryngoscope 89 pp. 43-58 (1979).
Kojima Jun
Otani Takeshi
Yanagida Shingo
Christie Parker & Hale LLP
Criares Theodore J.
Kia Jennifer
Nikken Chemicals, Co., LTD
LandOfFree
Method for treating Meniere's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating Meniere's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating Meniere's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2489267